Regulus Adds IP from Baltimore Lab
Luke Timmerman12/17/09
Regulus Therapeutics, the Carlsbad, CA-based developer of microRNA therapies, said today it has obtained an exclusive license from the lab of David Baltimore at Caltech to make drugs that affect a pair of microRNAs thought to be related to inflammation. Regulus is getting worldwide exclusive rights to develop drugs against miR-146 and miR-155. Baltimore is the chairman of Regulus’ scientific advisory board, and a member of the company’s board of directors. Financial terms of the deal weren’t disclosed.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
